As of Monday, May 18, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 9.02%, which has investors questioning if ...

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV Capsid Engineering Innovations TN-401 is Tenaya’s gene therapy candidate being developed for the ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Tenaya Therapeutics recently reported a reduced net loss of US$19.27 million for the first quarter of 2026 and, in April, ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...

Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m. EST TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the ...